Ginkgo Bioworks Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Ginkgo Bioworks Holdings

26/02/2025 24:02

Ginkgo Bioworks Holdings Inc DNA.N reported a quarterly adjusted loss of $2.00​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-4.40.  The mean expectation of five analysts for the quarter was for a loss of $1.77 per share. Wall Street expected results to range from $-2.57 to $-1.30 per share.

Revenue rose 26.2% to $43.85 million from a year ago; analysts expected $44.46 million.

Ginkgo Bioworks Holdings Inc's reported EPS for the quarter was a loss of $2.00​.

The company reported a quarterly loss of $107.53 million.

Ginkgo Bioworks Holdings Inc shares had risen by 6.5% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 4 "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "sell"

Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00

This summary was machine generated from LSEG data February 26 at 12:01 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-1.77
-2.00
Missed
Sep. 30 2024
-2.73
-0.94
Beat
Jun. 30 2024
-3.12
-2.80
Beat
Mar. 31 2024
-3.33
-3.20
Beat